SWOG clinical trial number
SWOG-9157

Trial of All Trans-Retinoic Acid in Hepatoma, Phase II.

Closed
Phase
Accrual
86%
Published
Abbreviated Title
Trial of All Trans-Retinoic Acid in Hepatoma, Phase II.
Activated
06/01/1993
Closed
08/01/1994

Research committees

Gastrointestinal Cancer

Publication Information Expand/Collapse

1998

Phase II trial of oral B-all trans-retinoic acid in hepatocellular carcinoma (SWOG-9157).

FL Meyskens Jr;J Jacobson;B Nguyen;GR Weiss;DR Gandara;JS Macdonald Investigational New Drugs 16(2):171-173

1996

Phase II trial of B-trans-retinoic acid (TRA) in primary hepatomas (SWOG-9157).

FL Meyskens Jr;B Nguyen;J Jacobson;J Macdonald American Society of Clinical Oncology 15:229(#559)

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/A022101

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
SWOG Clinical Trial Number
S2107

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
Accrual
71%
Open
Phase
SWOG Clinical Trial Number
S2104

A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Research Committee(s)
Gastrointestinal Cancer
Activated
10/14/2021
Accrual
27%
Open
Phase